Carmell Therapeutics Corporation Class A Common Stock

CTCX: Carmell Therapeutics Corp is a regenerative medicine biotech company focused on leveraging our core platform technology, Plasma-based Bioactive Material to stimulate tissue repair or growth after injury, disease or aging. The technology is a proprietary method of utilizing fresh frozen, platelet-enriched plasma to manufacture multiple forms to be placed directly at the anatomical site in need of enhanced and accelerated healing with the ability to reside in the local tissue for weeks to months.